Imatinib (STI571)

Catalog No.S2475

Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Imatinib (STI571) Chemical Structure

Imatinib (STI571) Chemical Structure
Molecular Weight: 493.6

Validation & Quality Control

Cited by 33 publications:

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PDGFR Inhibitors with Unique Features

Product Information

  • Compare PDGFR Inhibitors
    Compare PDGFR Products
  • Research Area

Product Description

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
IC50 100 nM 100 nM 600 nM
In vitro In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LAMA-84NF\sT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;4TWM2OD1yLkC3N|A1KM7:TR?=MYDTRW5ITVJ?
EM-2Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlT4TWM2OD1yLkC4PFgh|ryPNEXSUHNUSU6JRWK=
MEG-01NFLEW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH5TWM2OD1yLkC4PVIyKM7:TR?=MVrTRW5ITVJ?
BV-173MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMUi3OEDPxE1?NHzxXYxUSU6JRWK=
K-562M4jF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmm5TWM2OD1yLkKyOFMzKM7:TR?=M1freXNCVkeHUh?=
CGTH-W-1MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV60WFExUUN3ME2wMlM5Ozd2IN88US=>M{Pv[3NCVkeHUh?=
ST486M3\kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnnfJR4UUN3ME2wMlY5PTRizszNMnHmV2FPT0WU
NCI-H1436MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fab2lEPTB;MD65O|gxOSEQvF2=M1TPbnNCVkeHUh?=
NOS-1NFXCOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\6VmlEPTB;MT62OVM5OyEQvF2=NITaZWNUSU6JRWK=
A498M4P3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjKNmlKSzVyPUKuOVczOjNizszNM{XVSHNCVkeHUh?=
BE-13M2O2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHnTWM2OD1{Lk[yNVA3KM7:TR?=NVPacoE{W0GQR1XS
SUP-T1NIXmPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHVdoZnUUN3ME2zMlgzQTB5IN88US=>M4DvcXNCVkeHUh?=
NCI-H1770NEHaTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkX2TWM2OD13LkW3NlYzKM7:TR?=Mn3UV2FPT0WU
IMR-5NUf2UHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTyTWM2OD14LkKyNVQ4KM7:TR?=M2LsVnNCVkeHUh?=
LB2241-RCCMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjtOXpCUUN3ME24MlA4Ozh2IN88US=>MmL4V2FPT0WU
TGBC24TKBM37GRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRThwM{SwOVIh|ryPMnTkV2FPT0WU
SCC-15NXfGdXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DmOGlEPTB;MUCuO|c5QCEQvF2=NYPJc493W0GQR1XS
BB49-HNCNEDGWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfCTWM2OD1zND6zN|M2KM7:TR?=M2DMfHNCVkeHUh?=
ES7NVXadpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrZRnlKSzVyPUG0Mlc{PzlizszNNY\YWXRiW0GQR1XS
LB2518-MELNH3ZTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXhTWM2OD1zNj62NFk1KM7:TR?=Mn\WV2FPT0WU
NCI-H510AMnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\jbJQ4UUN3ME2xO{4zPDR{IN88US=>M{SxV3NCVkeHUh?=
TE-441-TMmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTF5LkK4PFYh|ryPNWrQfZFSW0GQR1XS
HHM4T3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFu3WplKSzVyPUG3MlM6QTlizszNM1G2UnNCVkeHUh?=
LC4-1NIfaSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTnblNwUUN3ME2xPE4xPjV{IN88US=>Mln4V2FPT0WU
KARPAS-45M4\GOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rRT2lEPTB;MUiuNVg1QCEQvF2=Mmr1V2FPT0WU
LB1047-RCCNEDEdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTF6LkS0OVIh|ryPNGjJd2tUSU6JRWK=
NKM-1M3fRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF7LkO1OVIh|ryPMkDCV2FPT0WU
SCLC-21HNULzXIt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3v3RWlEPTB;MkCuNVI1PiEQvF2=NUXJSo9pW0GQR1XS
RS4-11MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJyLkOzNFgh|ryPMmfLV2FPT0WU
ALL-POM1Lkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjOSIJKSzVyPUKwMlgyPDlizszNM4TGSHNCVkeHUh?=
GDM-1NWHNSGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJ{LkW5OFUh|ryPMYjTRW5ITVJ?
DMS-79M2HJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTJ2LkS5N|Qh|ryPM33ocnNCVkeHUh?=
MPP-89M3PCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{m4XWlEPTB;MkWuOlg4PCEQvF2=MoKzV2FPT0WU
NB10M1;CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HLNmlEPTB;Mk[uOFY6QSEQvF2=MVPTRW5ITVJ?
LS-513Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTJ4Lki4OFch|ryPM2TMV3NCVkeHUh?=
L-540MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkOxTWM2OD1{Nj65NVQ{KM7:TR?=M1zhOHNCVkeHUh?=
ES1Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\iSmZQUUN3ME2yO{42OjFizszNNIS0S3NUSU6JRWK=
NTERA-S-cl-D1M1HqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;WfJdKSzVyPUOwMlUxQTNizszNMn3oV2FPT0WU
EW-1Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTN{Lkm0OVQh|ryPMmq0V2FPT0WU
Calu-6MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjQTWM2OD1|Mz6xPFU2KM7:TR?=M1i1UHNCVkeHUh?=
CTV-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVS0doxDUUN3ME2zN{46Pzh7IN88US=>MVXTRW5ITVJ?
YTMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnkZmFKSzVyPUO4MlUzODlizszNMoPqV2FPT0WU
TE-6MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfUeGpKSzVyPUSxMlI4QThizszNNVy4Roo1W0GQR1XS
HT-144M4DZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTRzLkW0PFYh|ryPMX\TRW5ITVJ?
EW-13MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjjb2pKSzVyPUSyMlI4QTFizszNMUXTRW5ITVJ?
KALS-1Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTR|LkGzNlkh|ryPNWrJcpFPW0GQR1XS
MOLT-16NEmzWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFOyc|RKSzVyPUS1MlA4PTJizszNM4S0bHNCVkeHUh?=
D-336MGM3yydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTXcodKSzVyPUS1Mlk2QTlizszNM2rrcXNCVkeHUh?=
TE-11MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLjO21HUUN3ME20Ok43PTNizszNNXv0boVJW0GQR1XS
EB2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTR4Lk[5PUDPxE1?MoG3V2FPT0WU
SK-N-DZMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXjZXJsUUN3ME20PE4xQTZzIN88US=>M1jBTHNCVkeHUh?=
SW684MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TBdGlEPTB;NEiuNlY6PSEQvF2=NGixU3RUSU6JRWK=
EW-18MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jKeWlEPTB;NEiuOFM6PSEQvF2=MWjTRW5ITVJ?
RL95-2NVq2O2VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTXZll3UUN3ME21NE4xPzFizszNNVfMV5RTW0GQR1XS
CHP-126MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfJdVBJUUN3ME21NE45QTB3IN88US=>NEnr[mtUSU6JRWK=
NCI-H1395MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnMTWM2OD13MT63PFM2KM7:TR?=M1LkV3NCVkeHUh?=
TE-15NVq4S4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljETWM2OD13Mj6yOVU3KM7:TR?=M{XiPXNCVkeHUh?=
ES4MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTV{Lkm3O|Uh|ryPMlP5V2FPT0WU
TE-1NXnmbo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i5[2lEPTB;NUOuPVQ2PSEQvF2=Mo[3V2FPT0WU
SIMANXTqcFBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HhPWlEPTB;NUeuN|MyOSEQvF2=Mo\TV2FPT0WU
LB647-SCLCNXv0dFlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDwTFNKSzVyPU[0MlEyQDhizszNMlzoV2FPT0WU
KY821NF:xfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PBXWlEPTB;NkSuNlU2OiEQvF2=NGnZ[WtUSU6JRWK=
LC-2-adMkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLHTWM2OD14NT63OlAyKM7:TR?=MUfTRW5ITVJ?
KP-N-RT-BM-1NVGwRlRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzvcYRKSzVyPU[2MlY{PjZizszNMnWyV2FPT0WU
SW872NVLrcZFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrsO3JpUUN3ME22O{41Ozh{IN88US=>M{Oxb3NCVkeHUh?=
ES5MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDiTWM2OD14Nz62PVY5KM7:TR?=MYDTRW5ITVJ?
SK-NEP-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTZ6LkO4NFMh|ryPMYfTRW5ITVJ?
RPMI-6666M4f2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTdzLkCzNkDPxE1?MYPTRW5ITVJ?
UACC-812MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fNbmlEPTB;N{GuNVYxQSEQvF2=NFzaOpJUSU6JRWK=
COLO-829MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTd{Lk[5PFch|ryPM{DRUXNCVkeHUh?=
KP-N-YSM4DxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\yR2lEPTB;N{KuO|E{QSEQvF2=NX;pbmtHW0GQR1XS
GI-1MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXjOGdKSzVyPUezMlI5PjhizszNM3K2S3NCVkeHUh?=
ETK-1MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LMR2lEPTB;N{OuOFk{OiEQvF2=NXfUTlE{W0GQR1XS
LXF-289NUPOdnBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\iWmlEPTB;N{OuO|I6KM7:TR?=NWXlTWU{W0GQR1XS
CAS-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYm1W494UUN3ME23N{45QDV5IN88US=>NEi1eXdUSU6JRWK=
EW-22NWrkNmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTd2LkexNVUh|ryPNIDCVI9USU6JRWK=
NCI-H2196MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLaXplrUUN3ME23OU43Ozd7IN88US=>NEX5eppUSU6JRWK=
EoL-1-cellNXnrTW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLUTWM2OD16MT62PVY{KM7:TR?=NULFZoVIW0GQR1XS
D-247MGMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjzTWM2OD16Mj6wNlQ5KM7:TR?=NWrFO|JFW0GQR1XS
BeckerM2jre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTh{LkO0PFEh|ryPMmmwV2FPT0WU
IST-MEL1M2rmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfQS5JrUUN3ME24Nk4{PDh{IN88US=>MnziV2FPT0WU
MDA-MB-134-VINXLETXFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTh{LkW5PVYh|ryPNGfqWHpUSU6JRWK=
NCI-H1092M4SzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DqdmlEPTB;OESuNFE6PyEQvF2=NGTKWHlUSU6JRWK=
KINGS-1NWH4[mM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTh4LkG2NVgh|ryPMY\TRW5ITVJ?
HCC2218MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fofWlEPTB;OE[uO|kyOyEQvF2=M1myVXNCVkeHUh?=
GI-ME-NMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTh5Lke2PVkh|ryPNVL5e4w{W0GQR1XS
AM-38M2D3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3qclJ2UUN3ME24PE4{QTV|IN88US=>NUXhdmt4W0GQR1XS
KNS-42MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TBVGlEPTB;OEmuNVAyQCEQvF2=NHnEPZlUSU6JRWK=
C8166MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDGTpVKSzVyPUi5MlYyOjVizszNM2LXSnNCVkeHUh?=
Ramos-2G6-4C10M3PqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{GwTGlEPTB;OEmuPFcyQSEQvF2=Ml7SV2FPT0WU
CTB-1NVXzTXdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTlyLk[zOVch|ryPNELHfJJUSU6JRWK=
HCE-4M4W2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTzTWM2OD17MT6xN|M3KM7:TR?=NV2wU5p5W0GQR1XS
NCI-H526NXX0[|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4j5SGlEPTB;OUKuOFExOyEQvF2=M4\mcXNCVkeHUh?=
ECC4M4foTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTl2LkK1OVUh|ryPM4fjfHNCVkeHUh?=
NCCITM3vRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELnPFNKSzVyPUm1MlMzQTJizszNMoC0V2FPT0WU
MZ7-melNGL2S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEH3dohKSzVyPUm1MlkxPCEQvF2=NGLrWVlUSU6JRWK=
COLO-684MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTl4LkKzPFUh|ryPNH\3R5hUSU6JRWK=
SU-DHL-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPxfJZKSzVyPUm2Mlk5PDJizszNNYC1UIZvW0GQR1XS
SF126M2fIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInlSHRKSzVyPUm3MlUzOTdizszNMnHqV2FPT0WU
NMC-G1NUDDT2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3r0[2lEPTB;OUiuOFU2PCEQvF2=MlvDV2FPT0WU
NB14MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmj1TWM2OD17OD65NlA5KM7:TR?=NUDn[nFMW0GQR1XS
VA-ES-BJNF;zZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn2zTWM2OD17OT60NFU3KM7:TR?=M1;4[3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

PDGF receptor kinase activity PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.

Cell Assay: [3]

Cell lines BON-1 cells and NCI-H727 cells
Concentrations ~100 μM
Incubation Time 48 hours
Method BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.

Animal Study: [5]

Animal Models SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
Formulation Imatinib is diluted in water.
Dosages 70 or 100 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Buchdunger E, et al. Proc Natl Acad Sci USA. 1995, 92(7), 2558–2562.

[2] Heinrich MC, et al. Blood. 2000, 96(3), 925-932.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT02812693 Not yet recruiting Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma Joanne Jeter|National Cancer Institute (NCI)|Merck Ltd.|O  ...more Joanne Jeter|National Cancer Institute (NCI)|Merck Ltd.|Ohio State University Comprehensive Cancer Center September 2016 Phase 1|Phase 2
NCT02538926 Not yet recruiting B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T  ...more B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma University of Washington|National Cancer Institute (NCI) August 2016 Phase 2
NCT02685046 Recruiting Colonic Neoplasms UMC Utrecht|Meander Medical Center|Erasmus Medical Center  ...more UMC Utrecht|Meander Medical Center|Erasmus Medical Center|Hubrecht Institute April 2016 Phase 2
NCT02611492 Recruiting Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Assistance Publique - Hôpitaux de Paris April 2016 Phase 3

view more

Chemical Information

Download Imatinib (STI571) SDF
Molecular Weight (MW) 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms CGP057148B, ST-1571
Solubility (25°C) * In vitro DMSO 3 mg/mL (6.07 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-​[(4-​methyl-​1-​piperazinyl)​methyl]​-​N-​[4-​methyl-​3-​[[4-​(3-​pyridinyl)​-​2-​pyrimidinyl]​amino]​phenyl]​-benzamide

Frequently Asked Questions

  • Question 1
    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

    Answer: S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PDGFR Products

  • AZD2932

    AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.

  • Sunitinib

    Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Sunitinib Malate

    Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

  • CP-673451

    CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM in cell-free assays, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.

  • PP121

    PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.

  • Crenolanib (CP-868596)

    Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.

  • Tyrphostin AG 1296

    Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.

  • Sennoside B

    Sennoside B, a kind of irritant laxative isolated from rhei rhizome, inhibits PDGF-stimulated cell proliferation.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

Recently Viewed Items

Tags: buy Imatinib (STI571) | Imatinib (STI571) ic50 | Imatinib (STI571) price | Imatinib (STI571) cost | Imatinib (STI571) solubility dmso | Imatinib (STI571) purchase | Imatinib (STI571) manufacturer | Imatinib (STI571) research buy | Imatinib (STI571) order | Imatinib (STI571) mouse | Imatinib (STI571) chemical structure | Imatinib (STI571) mw | Imatinib (STI571) molecular weight | Imatinib (STI571) datasheet | Imatinib (STI571) supplier | Imatinib (STI571) in vitro | Imatinib (STI571) cell line | Imatinib (STI571) concentration | Imatinib (STI571) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us